Core Viewpoint - The newly revised "Management Measures for Information Disclosure of Listed Companies" has been officially implemented on July 1, 2023, incorporating recent regulatory practices and enhancing supervision of key matters [1][4]. Summary by Sections Implementation of New Regulations - The revised information disclosure measures were publicly solicited for opinions in December 2024 and officially released on March 28, 2023 [1]. - Key changes include strengthened risk disclosure requirements, increased regulation on outsourcing of information disclosure, and an adjustment of the maximum penalty to 100,000 yuan [1]. Companies Facing Penalties - On the first day of the new regulations, *ST Wan Fang and Ren Ren Le were publicly reprimanded for information disclosure issues [4][5]. - *ST Wan Fang initially forecasted a net profit of 20 million to 25 million yuan for 2024 but later revised it to a loss, leading to a public reprimand for failing to disclose accurate performance forecasts [4]. - Ren Ren Le also faced similar issues, with a significant discrepancy between its profit forecast and the audited results, resulting in a public reprimand [5]. Regulatory Actions and Statistics - In June, 18 companies were subjected to regulatory measures related to information disclosure, including failures in timely and accurate reporting [8]. - Specific companies like Jun Yao Health and Long Yang Technology were noted for not meeting disclosure standards in their performance forecasts [8]. - Two companies, Mei Chen Technology and Song Cheng Performing Arts, were penalized for accounting errors that led to inaccurate disclosures [9][11]. Additional Company Cases - ST Jing Gu received a regulatory letter regarding asset freezing and the need for risk disclosure, aligning with the new regulations' emphasis on risk factors [6][7]. - Companies like Heng Bang and Jing Yi failed to disclose critical information, receiving regulatory letters for their omissions [12]. Conclusion - The new information disclosure regulations aim to enhance transparency and accountability among listed companies, with immediate repercussions observed in the market [1][4][8].

Core Points - The company is established to protect the rights and interests of shareholders and creditors, and to regulate its organization and behavior according to relevant laws [3] - The company was formed by the restructuring of Juneyao Group Dairy Co., Ltd. and is registered in Yichang City with a registered capital of RMB 430 million [4][5] - The company focuses on the health beverage industry, aiming to become a leader in this sector in China while providing satisfactory services to customers and maximizing value for shareholders [13] Company Structure - The company has a registered capital of RMB 430 million and is a permanent corporation [4][5] - The company’s shares are issued in the form of stocks, with each share having a par value of RMB 1 [16] - The company’s total shares amount to 43 million, with major shareholders including Juneyao Group holding 32.5 million shares (65%) [19] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, participate in shareholder meetings, supervise company operations, and transfer their shares [33] - Shareholders holding more than 5% of voting shares must report any pledges of their shares to the company [39] - The company’s major shareholders and actual controllers must not harm the interests of the company or its public shareholders [40] Shareholder Meetings - The company holds annual shareholder meetings within six months after the end of the fiscal year [45] - Shareholder meetings can be called by the board of directors or by shareholders holding more than 10% of shares [51] - Decisions made at shareholder meetings require a majority or two-thirds majority vote depending on the type of resolution [78][80] Financial and Operational Governance - The company must seek shareholder approval for significant transactions, including those exceeding 30% of the latest audited total assets [14][17] - The company is required to maintain accurate records of shareholder meetings, including attendance and voting results [29][30] - The company must ensure compliance with legal and regulatory requirements during shareholder meetings and transactions [48][49]

Core Viewpoint - Hubei Junyao Health Beverage Co., Ltd. responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about trading financial assets, other receivables, and subsidiary equity acquisitions [1] Group 1: Trading Financial Assets - Junyao Health reported a year-end balance of trading financial assets of 155 million yuan, an increase of 84.27% year-on-year, with trust financial products accounting for 134 million yuan [2] - The trust plan "Aijian Win-Win - Shanghai Huade Accounts Receivable Debt Collection Fund Trust Plan" was established on July 28, 2023, with a term of 36 months and a maximum scale of 370 million yuan, raising 305.2 million yuan, with Junyao Health subscribing 130 million yuan at an annualized benchmark interest rate of 7.1% [2] Group 2: Other Receivables - The balance of other receivables at the end of the reporting period was 124 million yuan, with a bad debt provision of 16.16 million yuan [4] - The significant other receivables primarily stemmed from a partnership with Shengjiao Winery, which ended in December 2022, where Junyao Health is owed unconsumed prepayments [4] Group 3: Supply Chain Business - Junyao Health's supply chain business recognized sales revenue of 582 million yuan in 2024, down from 809 million yuan in the previous year [6] - The company engaged in transactions with Yihe (Shanghai) Supply Chain Management Co., Ltd., with procurement and sales amounts showing a downward trend [7] Group 4: Subsidiary Equity Acquisitions - During the reporting period, Junyao Health's subsidiary Meiri Boshi acquired three e-commerce companies, with the first two being established only 20 days prior to the acquisition [8] - The acquisitions aimed to quickly enter the online market and utilize existing e-commerce store qualifications to bypass platform review cycles, with the acquisitions being zero-cost [8]

湖北均瑶大健康饮品股份有限公司 章程 二〇二五年 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 | 7 | | 第一节 | 股东 | 7 | | 第二节 | 股东大会的一般规定 9 | | | 第三节 | 股东大会的召集 | 13 | | 第四节 | 股东大会的提案与通知 15 | | | 第五节 | 股东大会的召开 | 16 | | 第六节 | 股东大会的表决和决议 20 | | | 第五章 | 董事会 | 25 | | 第一节 | 董事 | 25 | | 第二节 | 董事会 | 29 | | 第三节 | 董事会秘书 | 34 | | 第六章 | 总经理及其他高级管理人员 36 | | | 第七章 | 监事会 | 37 | | 第一节 | 监事 | 38 | | 第二节 | 监事会 | 38 | | 第八章 | 财务会计制度、利润分配和审计 40 | | ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-041 湖北均瑶大健康饮品股份有限公司 关于修订《公司章程》并办理工商变更登记的公告 具体修改内容如下： 1 | 信息咨询服务）（除许可业务外，可 | | --- | | 自主依法经营法律法规非禁止或限制 | | 的项目） | 除上述条款外，《公司章程》的其他条款内容保持不变。 上述事项尚需提交公司 2025 年第二次临时股东大会审议，并提请股东大会 授权公司董事长及其再授权人士就上述事项办理工商变更登记手续。上述变更最 终以工商登记机关核准的内容为准。修订后的《公司章程》将于同日在上海证券 交易所网站(www.sse.com.cn)予以披露。 特此公告。 湖北均瑶大健康饮品股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于 2025 年 7 月 2 日召开第五届董事会第十五次会议审议通过了《关于修订<公司章程>并办理工 商变更登记的议案》，尚需提交 2025 年第二次临时股东大会审议。现将具体 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-042 重要内容提示： 湖北均瑶大健康饮品股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 23 日 14 点 00 分 召开地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 股东大会召开日期：2025年7月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 23 日 至2025 年 7 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-040 湖北均瑶大健康饮品股份有限公司 第五届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 公司根据《公司法》《上市公司章程指引》等法律、行政法规、部门规章、 规范性文件的规定，结合公司实际情况，拟对《公司章程》部分条款进行修订， 并办理工商变更登记（备案）手续。 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的《湖 北均瑶大健康饮品股份有限公司关于修订<公司章程>并办理工商变更登记的公 告》（公告编号：2025-041）。 表决结果：同意：9 票，反对：0 票，弃权：0 票。 此议案尚需提交股东大会审议。 1 （二）审议通过《关于提请召开公司 2025 年第二次临时股东大会的议案》 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的《湖 北均瑶大健康饮品股份有限公司关于召开 2025 年第二次临时股东大会的通知》 （公告编号：2025-042）。 表决结果：同 ...

Core Viewpoint - Junyao Health is expanding its probiotic functional dairy beverage products into major retail channels, indicating a significant growth trajectory in the probiotic market, supported by strong revenue growth and innovative product offerings [1][3][4]. Group 1: Product Launch and Market Expansion - Junyao Health's probiotic drinks, including "Daily Dream" and "Daily Brightness," have launched in 2,700 Lawson convenience stores and 70 Ole supermarkets in East China, emphasizing a "scene-based functional probiotic" concept [1]. - The company reported a 139.19% year-on-year revenue growth in its probiotic segment for Q1 2025, with overseas market growth at 77.43%, highlighting the importance of channel upgrades [1][7]. - The introduction of innovative products like AKKBG-001™ and OralBubble™ during major health exhibitions showcases Junyao's commitment to product innovation [1][2]. Group 2: Industry Position and Competitive Landscape - Junyao Health has established a comprehensive "R&D-production-sales" integrated chain in the probiotic industry, creating a significant technological barrier [2][4]. - The company is recognized as a leader in the probiotic sector, with over 40,000 proprietary probiotic strains and collaborations with top universities to enhance product competitiveness [2][4]. - The rapid growth of the probiotic market in China, projected to reach nearly 200 billion yuan by 2028, has attracted over 4,600 related enterprises, intensifying competition [3][4]. Group 3: Channel Development and E-commerce Growth - Junyao Health is expanding its distribution channels, including partnerships with e-commerce platforms like Pinduoduo and strategic agreements with major clients [5][6]. - The company's e-commerce revenue surged by 1173.33% year-on-year in Q1 2025, reflecting the growing importance of online sales in the health product sector [5][6]. - The integration of a supply chain model that connects raw materials, products, and channels is a key factor in Junyao's market positioning [5][6]. Group 4: International Market and Future Outlook - Junyao Health's international business achieved approximately 84.6 million yuan in revenue in 2024, with a 24.54% year-on-year increase, and a 77.43% growth in Q1 2025 [7][8]. - The company is recognized as the largest exporter of probiotics in China, with products sold in over 80 countries, establishing a strong global presence [7][8]. - With ongoing support from policies and a focus on health consumption upgrades, Junyao Health is positioned for sustained growth and market expansion [8].

Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response to clarify various financial transactions and disclosures related to its investments and financial assets [1][2]. Group 1: Financial Performance and Investments - The company's trading financial assets at the end of the reporting period amounted to 155 million yuan, representing an 84.27% year-on-year increase, with trust financial products accounting for 134 million yuan [3]. - The company purchased trust products from Shanghai Aijian Trust Co., Ltd., with a total subscription of 130 million yuan, aimed at optimizing asset allocation and enhancing financial returns [5][6]. - The trust plan raised a total of 305.2 million yuan, with the company being a significant investor, indicating a strategic move to utilize idle funds effectively [15]. Group 2: Risk Management and Asset Quality - The underlying assets of the trust products are receivables from Shaanxi Dijiang Real Estate Group, which is supported by a funding commitment from its parent company, ensuring the trust's repayment capacity [9][10]. - The company has implemented measures to mitigate credit risk, including joint management of payment processes and maintaining oversight of the underlying asset's financial health [12][14]. - The trust product's underlying assets are linked to a state-owned enterprise, which adds a layer of security to the investment, although macroeconomic factors could still pose risks to the real estate sector [10][11]. Group 3: Corporate Governance and Compliance - The company conducted a self-assessment of its transactions with Aijian Trust to ensure fairness and compliance with regulatory standards, confirming that no benefits were improperly transferred to controlling shareholders [15][21]. - The investment decisions were made following internal approval processes, ensuring adherence to legal and regulatory requirements, thus maintaining corporate governance standards [21][22]. - The company has documented its financial transactions and the rationale behind its investment strategies, reinforcing transparency and accountability in its operations [19][20].

关于湖北均瑶大健康饮品股份有限公司 2024 年年度报告的信息披露监管问询函的回复 众环专字（2025）2300451 号 目 起始页码 国复 | 众环会计师事务所(特殊普通合伙 市中北路 166 号长江产业大厦 17-18 电话 Tel: 027-86791215 传直 Fax: 027-85424329 关于湖北均瑶大健康饮品股份有限公司 2024 年年度报告的信息披露监管问询函的回复 众环专字（2025）2300451 号 上海证券交易所上市公司管理一部: 回复第1页共 36 页 关于湖北均瑶大健康饮品股份有限公司 2024 年年度报告的信息披露监管问询函的回复 公司回复: 中审众环会计师事务所(特殊普通合伙)(以下简称"本所"或"我们")作为湖北均瑶大 健康饮品股份有限公司(以下简称"均瑶健康公司")2024年度财务报表的审计机构,于 2025 年 4 月 29 日出具了众环审字[2025]2300487 号无保留意见审计报告。 2025 年 6 月 4 日,上海证券交易所上市公司管理一部出具了《关于湖北均瑶大健康饮 品股份有限公司 2024 年年度报告的信息披露监管问询函》(以下简称"问询函"),我 ...